News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Settlement Between BioPorto And Phadia AB In Patent Case


3/3/2014 8:55:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BioPorto and Phadia have reached a settlement in the case before the Supreme Court No. 206/2012 regarding the revocation of Phadia’s patent DK/EP 0756 708, which cites the use of HNL (another designation of NGAL) as a diagnostic marker of human illness.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES